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Abstract 
Prescription opioid misuse is a serious public health concern, yet antecedent factors are 
poorly described. Using data from the National Longitudinal Study of Adolescent to Adult Health 
(Add Health) (n = 14,784), we examined the longitudinal relationship between history of 
adolescent chronic pain and odds of misusing prescription opioids in adulthood. The primary 
predictor variable was chronic pain status during adolescence. The primary outcome variables 
were prescription opioid misuse during early adulthood and adulthood. Multivariate models 
controlled for known risk factors of opioid misuse, including sociodemographics (sex, race and 
ethnicity), adolescent mental health symptoms (anxiety, depression), adolescent self-reported 
physical health status, adolescent substance use/abuse, childhood trauma, and adult legitimate 
opioid use. We found that adults with a history of adolescent chronic pain were more likely to 
misuse opioids compared to those without history of chronic pain, even after controlling for other 
known risk factors. Further, we found that among individuals with history of adolescent chronic 
pain that race (white), other substance use, and exposure to trauma were risk factors for later 
opioid misuse. Longitudinal associations between adolescent chronic pain and subsequent adult 
prescription opioid misuse highlight the need for early targeted screening and prevention efforts 
that may reduce later opioid misuse. 
 
 
Perspective 
Using a large nationally representative sample, we found that chronic pain during adolescence 
was an independent risk factor for opioid misuse in adulthood, over and above other known risk 
factors. Furthermore, among those individuals with adolescent chronic pain, substance use, 
exposure to trauma, and race was associated with opioid misuse. 
 
Keywords 
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Introduction 
Prescription opioid misuse is defined as the consumption of opioids in manner or dose 
other than prescribed, consuming others’ prescriptions, or consuming opioids for feelings that 
are elicited (i.e. to get high)31. Prescription opioid misuse is a serious  public health epidemic in 
the United States. In 2013, almost 10 million Americans (4.9% of the adult population) reported 
prescription opioid misuse 15. Prescription opioid misuse was found to be most prevalent among 
young adults 18-26 years of age, of whom 7.1% reported opioid misuse over the past 12 
months in 2016 in the United States 4. Cumulatively, by age 28, almost 23- 30% of Americans 
report misusing opioids at some point during their lifetime according to data from the National 
Longitudinal Study of Adolescent Health (Add Health; 2008) and National Survey on Drug Use 
and Health (2014) 45, 3.  
Prescription opioid misuse among young adults is associated with severe consequences 
including reduced employment1, sexual victimization19, and driving under the influence52. 
Furthermore, opioid misuse is a key antecedent for opioid  use disorder, which may be 
characterized as a problematic pattern of opioid use that causes significant impairment or 
distress5. Indeed, opioids accounts for >50% of drug-related emergency department visits 30 and 
unintentional opioid overdose deaths now exceed those for all other illicit drugs in the USA40.  In 
2016, 2.1 million Americans reported having an opioid use disorder4. 
Risk factors for opioid misuse remain poorly understood, yet many of the risk factors 
identified thus far are already present during adolescence including a history of substance 
abuse25, anxiety and depressive symptoms9, a history of childhood trauma37, higher 
socioeconomic status45, female sex 28, and white, non-Hispanic race26. Better identification of 
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risk factors would allow targeted screening and prevention efforts during childhood, reducing the 
incidence and negative impact of later opioid misuse. 
Chronic pain in adolescence is a potentially important individual difference factor that 
may help explain risk of prescription opioid misuse. Chronic pain affects 15-25% of 
adolescents21 and adolescents with chronic pain share some similar characteristics to those 
who develop prescription opioid misuse, including an increased prevalence of exposure to  
childhood trauma16 and increased rates of anxiety and depression32. Furthermore, a recent 
meta-analysis found that 25% of adults with chronic pain misuse prescription opioids50.  
However, studies have not yet identified whether having chronic pain during adolescence is 
associated with increased risk for future prescription opioid misuse in adulthood.  
Thus, the primary aim of this study was to determine associations between adolescent 
chronic pain and subsequent prescription opioid misuse in adulthood in a large, nationally 
representative sample of individuals in the United States. We hypothesized that adults with a 
history of chronic pain during adolescence were more likely to misuse prescribed opioids, over 
and above other known risk factors of opioid misuse, including sociodemographic variables 
(sex, race, ethnicity, and income), adolescent mental health symptoms (anxiety and 
depressive), adolescent substance use/abuse, history of childhood trauma, and legitimate 
opioid use during adulthood. Our second aim was to explore specific risk factors associated with 
subsequent prescription opioid misuse in adulthood among individuals with a history of 
adolescent chronic pain. We hypothesized that the following risk factors in adolescence would 
predict increased risk for prescription opioid misuse in adulthood: higher household income, 
greater anxiety and depressive symptoms, greater substance use scores, and a larger number 
of traumatic experiences in childhood. Findings from these analyses will provide health care 
providers with a better understanding about which of their adolescent patients with chronic pain 
are at increased risk for future problematic opioid use. 
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Methods 
Participants and procedure 
 For this cross-sectional analysis we used data from the National Longitudinal Study of 
Adolescent Health (Add Health)29. Add Health is a nationally representative, stratified, random 
sample of 20,745 United States participants starting in 1995 when participants were 11-21 years 
of age (Mage = 16 years, S.D = 1.7 years). Add Health combines longitudinal survey data on 
respondents’ sociodemographic factors, physical and mental health, and substance use, 
providing unique opportunities to study how risk factors in adolescence are linked to health 
outcomes in adulthood. 
Add Health uses a complex, multistage sample design and oversamples minorities. By 
applying survey weights, estimates are representative of the United States population. Thus far, 
participants have completed four subsequent waves of in-home interviews, the most recent of 
which was in 2008 when participants were between the ages of 24 and 34 years (Mage = 29 
years, S.D = 1.7 years). Waves include: Wave I (adolescents 11–21 years of age, assessed in 
1995); Wave II (adolescents 12-22 years of age, assessed in 1996); Wave III (early adulthood, 
18–28 years of age, assessed in 2002); and Wave IV (adulthood, 24–34 years of age, assessed 
in 2008). We extracted data from all 4 Waves. The sample size included participants who 
completed all of the relevant items and waves (n = 14,784). Participant characteristics are 
presented in Table 1. Additional information on Add Health is available at 
http://www.cpc.unc.edu/projects/addhealth. Add Health data are publically available and 
therefore the Institutional Review Board at Seattle Children’s Hospital deemed this study 
exempt from review. 
 
Measures 
Figure 1 outlines Add Health waves and measures assessed at each time point.  
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Chronic pain. Adolescents completed a general health survey during Waves I and II, 
which assessed pain location and frequency. Adolescents were asked to rate the frequency of 
common types of pain conditions over the previous 12 months (headache, stomachache, and 
aches, pain, or soreness in muscles or joints). Adolescents reported whether they experienced 
each pain “never,” “just a few times,” “about once a week,” “almost every day,” or “every day.” 
We dichotomized pain as “chronic” or “not chronic.” To avoid overinflating rates and keeping 
consistent with definitions of “high-frequency pain” used in previous literature, we used a 
conservative classification of chronic pain to include pain occurring “almost every day” or “every 
day,” consistent with previous publications using data from Add Health32, 47. Moreover, 
prevalence rates of chronic pain within this data set (21.9%) were similar to those cited in 
previous research21. 
Prescription opioid misuse. Prescription opioid misuse was measured in the Waves 
following chronic pain measurement. Thus, while chronic pain was measured at Waves I and II, 
prescription opioid misuse was measured in Waves III and IV. Specifically, in the Add Health 
study, assessments were conducted to identify which participants initiated prescription opioid 
misuse between Waves II and III, and again between Waves III and IV. This design allowed us 
to determine which individuals had chronic pain in adolescence prior to reporting prescription 
opioid misuse in adulthood. 
We used self-report data from Waves III and IV to measure cumulative prescription 
opioid misuse. The exact item stems varied slightly across Waves, reflecting different opioids 
available in the United States between Waves. Wave III prescription opioid misuse was 
identified by the following question: “Since June 1995 (Wave II), have you taken any of the 
following drugs without a doctor’s permission: pain killers such as Darvon, Demerol, Percodan 
or Tylenol with codeine?” with a binary response option of “yes” or “no”. Wave IV prescription 
opioid misuse was identified by the following question:  “Which of the following prescription 
drugs have you taken that were not prescribed for you, taken in larger amounts than prescribed, 
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for longer periods than prescribed, or that you only took for the feeling or experience they 
caused: pain killers or opioids such as Vicodin, OxyContin, Percocet, Demerol, Percodan or 
Tylenol with codeine not prescribed?” with a binary response option of “yes” or “no”. For 
analyses, responses at each wave were coded as a binary variable, no opioid misuse = 0 and 
any opioid misuse = 1.   
Sociodemographics: During Wave I adolescents reported their age, sex, race, and 
ethnicity. Parents reported their household income. 
Anxiety symptoms: Adolescents completed a questionnaire assessing five 
physiological anxiety symptoms during Wave I. This approach has been used in previous Add 
Health studies18 to access anxiety symptoms. Specifically, adolescents were asked the 
frequency of each of the following symptoms over the past 12 months: (1) felt hot all over 
suddenly, for no reason; (2) cold sweats; (3) chest pains; (4) fearfulness; and (5) trouble 
relaxing. Responses to each item were measured using a 5-point Likert scale (anchors: 0 = 
“never”; 4 = “every day”). Similar to previously published research using this variable in the Add 
Health database, total anxiety symptom scores were calculated as a sum of the 5 items, with a 
possible range from 0 (no anxiety symptoms) to 20 (frequent/severe anxiety symptoms)18. 
Depressive symptoms: Adolescents completed the 20-item Center for Epidemiologic 
Studies-Depression Scale (CES-D) at Wave I. Items were scored based on the frequency at 
which depressive symptoms were experienced in the past week using a 4-point Likert scale 
(anchors: “never/rarely” and “most/all of the time”). Similar to previously published Add Health 
studies, total scores were calculated as a sum of the 20 items and could range from 0 (no 
depressive symptoms) to 60 (frequent/severe depressive symptoms)41.  
General health: Adolescents responded to the question “In general, how is your 
health?” with 5 response options ranging from “excellent” to “poor” in Wave I. For analyses, 
response options were dichotomized as either “good” (responses of “excellent,” “very good,” or 
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“good”) or “fair-poor” (responses of “fair” or “poor”). For analyses, the referent of “fair-poor” was 
coded as 0 and “good” was coded as 1. 
Other substance use in adolescence: At Wave 2, adolescents responded to the 
following 6 items assessing other substance use behaviors:  “Have you” (1) “ ever regularly 
smoked one or more cigarettes per day”, (2) “had 5 or more drinks in a row over the past 12 
months’, (3) “ever tried marijuana”, (4) “ever tried cocaine”,(5) “ever tried inhalants, such as 
glue”, and (6) “ever tried any other illegal drugs such as LSD, PCP, heroin, pills, etc”. Response 
options for all 6 items were binary (“yes” vs. “no”). Prior Add Health publications have used 
these items to characterize substance use behaviors during adolescence45.For analyses, we 
summed these six dichotomous variables (“yes” = 1, “no” = 0) to create a continuous variable 
representing 0-6 total substances used where higher scores indicate a greater number of 
substances used. 
Childhood trauma: Using data from Waves I, III, and IV, adolescents responded to 9 
items assessing exposure to childhood trauma. Specifically, adolescents were asked how often 
the following happened: (1) “being left alone when an adult should have been present >6 times”; 
(2) “not having adults taking care of their basic needs >6 times”; (3) “being slapped, kicked, or 
hit by an adult caregiver >6 times”; (4) “being touched in a sexual way or being forced to touch 
an adult in a sexual way”; (5) “having Social Services investigate or try to take them out of their 
living situation”; (6) “witnessed or threatened with physical violence”, (7) “someone stabbed 
you”, (8) “someone shot at you”; or (9) “someone physically assaulted/beaten you up”. 
Response options for all 9 items were binary (“yes” vs. “no”), Consistent with previously 
published Add Health studies 13, we summed these nine dichotomous variables (“yes” = 1, “no” 
= 0) to create a continuous variable representing 0-9 total individual traumas experienced during 
childhood 37.  
Legitimate opioid use during adulthood: During Wave IV interviewers asked 
participants to provide information on all prescription medications consumed in the last four 
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weeks.  These medications were categorized into therapeutic classes using the Multum 
Lexicon™ database. We identified all participants who reported taking a prescribed opioid.  
 
Statistical analysis plan.  
All analyses were conducted using the survey package contained in Stata version 12.1 
(StataCorp College Station, TX); α was set at .05.  We adjusted for the complex sample design 
of Add Health by using sampling weights, regional stratification, and primary sampling unit 
information to provide nationally representative estimates of the USA population.  
To address aim one, we directly compared rates of prescription opioid misuse at both 
Wave III and Wave IV between adults who had chronic pain as adolescents to those who did 
not have chronic pain as adolescents. Next, we performed multivariate logistic regression 
analysis to determine the association between adolescent chronic pain status and adult 
prescription opioid misuse after controlling for other known risk factors including 
sociodemographic factors (sex, race and ethnicity, income), mental health (anxiety and 
depressive symptoms), physical health, other adolescent substance use/abuse, and exposure 
to childhood trauma. We also include legitimate opioid use during Wave IV as a co-variate in our 
model assessing associations between history of adolescent chronic pain and opioid misuse at 
Wave IV. However, we should note, that inclusion versus exclusion of this covariate did not 
affect the size or direction of our estimated odds ratios.  
To address our second aim we used multivariate logistic regression analyses selecting 
only participants with history of chronic pain during adolescence to determine the association 
between hypothesized risk factors and subsequent prescription opioid misuse during adulthood 
among individuals with history of adolescent chronic pain.  The dependent variable used in aim 
2 was cumulative opioid misuse at Wave IV.  
 
Results 
10 
 
Sample description 
Our sample included 14,784 participants weighted to represent 21.93 million individuals 
nationally. Of these, 3,174 (weighted percentage: 21.9%) reported having chronic pain during 
adolescence. Sample characteristics, subdivided by chronic pain status, are presented in Table 
1. Females reported chronic pain more frequently compared than males: while females 
represented 49.3% of the entire sample, they represented 57.4% of those with chronic pain. 
Adolescents with chronic pain, on average, reported higher depressive and anxious symptoms, 
and were more likely to rate their general health as fair or poor compared to adolescents without 
chronic pain. We also found that adolescents with chronic pain reported higher scores on both 
substance use and childhood trauma exposure variables compared to those without chronic 
pain.   
 
Aim 1: Association between adolescent chronic pain history and prescription opioid 
misuse during early adulthood (Wave III) and adulthood (Wave IV). 
In the full sample, 19.9% of individuals reported initiation of prescription opioid misuse 
between Wave II (12-22 years of age; 1996) and Wave III (18-28 years of age; 2002; Table 1). 
Furthermore, an additional 8.4% of individuals reported initiation of prescription opioid misuse 
between Wave III and Wave IV (24-34 years of age; 2008). Thus, we found that by Wave IV, 
3,248 participants (weighted percentage: 28.3%) endorsed prescription opioid misuse. The rate 
of reported prescription opioid misuse in early adulthood was higher among individuals with a 
history of reported adolescent chronic pain compared to those without chronic pain (24% versus 
18.8%, p<0.001). Similarly, the rate of reported prescription opioid misuse in adulthood was also 
higher among individuals with a history of adolescent chronic pain versus those without (33% 
versus 27%, p<0.001). After controlling for multiple factors as specified in our logistic regression 
models, individuals with history of adolescent chronic pain had significantly increased odds of 
reported prescription opioid misuse in both early adulthood (adjusted odds ratio (AOR) = 1.24; 
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95% confidence interval (CI) 1.05-1.46, p = 0.013; Table 2) and adulthood (AOR = 1.19; 95%CI: 
1.04-1.36, p = 0.01). We also found that younger participants were more likely to report opioid 
misuse compared to older participants, and that females were less likely to report opioid misuse. 
In addition black and Hispanic participants were less likely to report opioid misuse compared to 
white participants. Having a history of adolescent substance use and childhood trauma was 
associated with increased odds of reported opioid misuse. Legitimate opioid use in the 
preceding 4 weeks was associated with increased odds of opioid misuse. Self-reported 
depressive and anxiety symptoms and overall physical health reported as fair or poor were not 
associated with prescription opioid misuse.  
 
Aim 2: Predictors of prescription opioid misuse within adults with a history of adolescent 
chronic pain. 
Table 3 presents results from our multivariate logistic regression analysis examining 
associations between adolescent risk factors and subsequent adult prescription opioid misuse 
among participants who had a history of adolescent chronic pain. Our findings partially 
supported our hypotheses. When investigating race, white adolescents were more likely to 
misuse opioids in adulthood than black adolescents (AOR = 0.40; 95%CI 0.23-0.69) and 
Hispanic adolescents (AOR = 0.42; 95% CI 0.25-0.71). Females were less likely to misuse 
opioids than males (AOR = 0.67; 95% CI 0.52-0.86). Contrary to our hypotheses, we did not find 
that higher depressive (AOR = 0.99; 95% CI 0.98-1.01) or anxiety symptoms (AOR = 1.02; 95% 
CI 0.96-1.08) were associated with prescription opioid misuse. However, higher scores on 
adolescent substance use (AOR = 1.27; 95% CI 1.17-1.39) and childhood trauma exposure 
(AOR = 1.38; 95% CI 1.21-1.58) were significantly associated with increased likelihood of 
misusing opioids in adulthood. 
 
Discussion 
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In this secondary analysis of an ongoing longitudinal survey we examined whether 
adolescent chronic pain increases risk for subsequent prescription opioid misuse in adulthood 
using a nationally representative sample of individuals in the United States. As we 
hypothesized, chronic pain status in adolescence was associated with an increased risk for 
prescription opioid misuse in early adulthood and adulthood over and above other known 
demographic and clinical covariates. Specifically, we found that the rate of opioid misuse in 
early adulthood was higher among individuals a history of adolescent chronic pain (24%) 
compared to those without a chronic pain history (19%). Similarly, the rate of opioid misuse in 
adulthood was higher among individuals with a history of adolescent chronic pain (33%) 
compared to those without a chronic pain history (27%). Our finding that 19.9% of 18-26 year 
olds misused opioids is similar to a previous report from the National Survey on Drug Use and 
Health, which found that 20.2% of 18-25 year old Americans had misused pain relievers in 2014 
3.  
Among the sub-sample of individuals with a history of adolescent chronic pain, we also 
sought to identify risk factors for later prescription opioid misuse. Consistent with our 
hypothesis, we found that youth who were white, female, used other substances, and had a 
history of exposure to childhood trauma were particularly vulnerable to opioid misuse in 
adulthood. This pattern of results is generally consistent with prior research which has also 
found that opioid misuse is more likely among white children (as compared to racial and ethnic 
minority youth)26, youth who use marijuana or engage in binge drinking28, and youth with a 
history of physical abuse or assault 37. Our finding that adolescent females may be at higher risk 
for later opioid misuse compared to males is somewhat difficult to interpret due to mixed 
findings in prior literature. For example, some epidemiologic studies have also identified a 
higher risk for opioid misuse among females43, while others have found females to be at either 
lower risk 20 or equivalent risk compared to males 26. The etiology of the racial and ethnic 
differences in opioid misuse identified in our study and others is also poorly understood. For 
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example, a recent study examining racial and ethnic differences in opioid use between Mexican 
American adults vs. Non-Hispanic white and black American adults indicated that patient 
preferences and cultural values may influence differential rates of opioid use between racial and 
ethnic groups17. To our knowledge, similar research has not yet been conducted in pediatric 
populations.  
Contrary to our hypothesis, symptoms of depression and anxiety among adolescents 
with chronic pain were not associated with later risk for opioid misuse. Psychological factors 
have been implicated in the persistence of chronic pain from adolescence to adulthood, 
including negative affect and pain catastrophizing 51, yet the precise role of psychological 
functioning in the development of opioid misuse remains unclear. For example, Grattan et al. 
found that depression was associated with opioid misuse among adults with chronic pain12, 
while Hah et al. found that depression and anxiety were not associated with opioid misuse 
among adults with chronic pain in multivariate models14.  On the other hand, Quinn et al. 
recently found strong associations between mental health diagnoses, including anxiety and 
depression, and long-term opioid use in adolescents although opioid misuse was not examined 
in that study 38. Potential shared biological mechanisms between chronic pain and opioid use in 
childhood are also largely unexplored, although there has been some work in this area in animal 
models and adult populations that may be informative. In a recent review, Finan and colleagues 
(2017) proposed that chronic pain states may lead to changes in dopaminergic 
neurotransmission and mesolimbic system functions involved in the perception of pain, reward, 
and pain relief. Increased risk for problematic opioid use is proposed to result directly from these 
neurobiological changes, or may occur indirectly via changes in psychological functioning (i.e., 
increased negative affect, pain catastrophizing, pain-related fear)8. Limited available research 
suggests that, similar to their adult counterparts, youth with chronic pain also experience 
alterations in brain regions involved in pain processing, reward, and pain-related fear, with the 
amygdala being of particular importance 44.  Furthermore, both chronic pain and opioid misuse 
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are associated with genetic polymorphisms in dopaminergic pathways. For example, dopamine 
D2 receptors (DRD2)36 and dopamine active transporters have been shown to alter pain 
perception and response to experimental pain in animal models and in adults with chronic pain 
conditions53.  Dopamine has also been identified as an important contributor to the opioid 
reward system as evidenced by associations between opioid addiction and reduced expression 
of DRD2 receptors in the brain46, 11. 
In addition to potential shared biological and psychological mechanisms, it is also 
important to consider social factors driving opioid use and the subsequent opioid epidemic in the 
United States. For example, recent nationwide increases in opioid prescribing to children and 
adolescents10 may be attributed to the confluence of several societal changes including a 
growing understanding of pediatric pain21 and its negative consequences39, increased vigilance 
towards pain management by regulatory agencies, and increased marketing of opioid 
medications to patients and providers by pharmaceutical companies. Treating pain with opioids 
is associated with increased risky opioid behaviors later in life2. For example Miech et al.28 found 
that legitimate opioid use during adolescence was associated with a 33% increased risk for 
opioid misuse before age 23, while McCabe et al.24 also found that that legitimate opioid use 
during adolescence was associated with opioid misuse at age 35. Next steps in this line of work 
should account for broader societal factors that may influence opioid prescribing practices and 
subsequent community-level and nationwide risk for opioid misuse and abuse across the 
lifespan. Our findings also suggest that a history of trauma and other substance use in 
adolescence may increase risk for opioid misuse later in life.   
For youth with chronic pain conditions who may benefit from opioid medications, an 
important clinical consideration is ensuring adequate pain relief while minimizing risks of opioid 
misuse, overdose, and opioid use disorder. This is of particular importance for pediatric 
populations, as untreated or undertreated pain in childhood has the potential to substantially 
disrupt neurobiological42 and psychosocial development34, and persist into adulthood51. It is 
15 
 
important to recognize that even for youth with chronic pain conditions who have a legitimate 
need for opioid medication, the gold standard for the management of pediatric chronic pain is 
interdisciplinary pain care, which may include pharmacotherapy but emphasizes the important 
role of behavioral pain management interventions, physical and occupational therapy, and 
complimentary and alternative modalities 23. While we did not examine legitimate opioid use 
among adolescents in this study, our findings support the need for development of guidelines 
aimed at reducing risk for opioid misuse among children and adolescents with chronic pain.7  
Consistent with prior research, our findings indicate that the majority of prescription 
opioid misuse was initiated between adolescence and early adulthood4. This suggests that 
adolescence may be a critical time for clinicians to identify risk for later opioid misuse and, 
potentially, to deploy preventive interventions directed at substance use behaviors. For 
example, adolescents often have unrestricted access to opioid medications at home 27, and a 
recent survey found that 1 in 4 adolescents did not consider prescription opioid misuse to be a 
risky behavior35. Our findings support existing recommendations for health care providers, 
parents, and adolescents receiving an opioid prescription to receive education about: 1) the 
impact of prescription drug misuse on the developing brain; 2) safe storage and disposal of 
opioid medications in the home; and 3) prescription drug monitoring33. Our findings suggest that 
adolescents at increased risk for later opioid misuse (e.g., presence of chronic pain, other 
substance use, history of exposure to childhood trauma) may require closer monitoring to 
ensure appropriate use of opioid medications.  
Findings from this secondary data analysis should be interpreted in the context of 
several limitations. First, chronic pain status in adulthood was not assessed in the Add Health 
survey; as a result, we cannot distinguish rates of opioid misuse between adults with vs. without 
concurrent chronic pain. Second, legitimate use of prescription opioids during adolescence was 
not assessed in the Add Health survey. Therefore, we are not able to determine rates of co-
occurring opioid use and chronic pain in our sample prior to early adulthood and we are unable 
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to make conclusions about associations between opioid use and misuse in our sample. Third, 
opioid misuse was assessed using a single self-report item, and other factors related to patterns 
and drivers of opioid misuse were not assessed (e.g., frequency, motivation for misuse). As a 
result, we were not able to evaluate potentially relevant nuances such as differences by opioid 
type and the impact of motivation on the initiation of opioid use and misuse behaviors. To our 
knowledge, this limitation is not unique to our study as more comprehensive self-report 
measures of opioid misuse risk have not yet been validated for adolescent populations. 
Furthermore, existing measures developed for adult populations have demonstrated poor 
psychometric properties and limited clinical utility (see Voon, Karamouzian & Kerr, 2017 for a 
comprehensive listing)49, 6.  Finally, different questions were used to assess opioid misuse in 
Wave III vs. Wave IV, which may have impacted our findings.  Specifically, Wave IV asks about 
Oxycodone, Vicodin and Percocet, while Wave IV also includes more detail on opioid misuse 
behaviors.  The less comprehensive approach in Wave III may have led to underestimation of 
opioid misuse prevalence at that time point.   Despite these limitations, the results from this 
study contribute to the limited evidence on the association between pediatric chronic pain and 
prescription opioid misuse.  
In conclusion, this is the first nationally representative study to examine whether chronic 
pain in adolescence is associated with opioid misuse in adulthood. Chronic pain affects 15-25% 
of adolescents and is associated with increased risk for poor clinical outcomes in adulthood, 
including mental 48 and physical health symptoms 51 and alcohol and tobacco use 22. Our study 
extends knowledge of the long-term outcomes associated with adolescent chronic pain by 
investigating subsequent prescription opioid misuse in adulthood. Our findings provide evidence 
that opioid misuse is more likely for adults with vs. without a history of adolescent chronic pain. 
This longitudinal association is of high public health importance, because the prescription opioid 
epidemic severely affects individuals in the United States across the lifespan. Early identification 
of at-risk individuals may minimize later prescription drug misuse. In our study, several risk 
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factors for opioid misuse later in life were identified including white race, female sex, other 
substance use, and history of childhood trauma.   
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Figure 1. National Longitudinal Study of Adolescent to Adult Health (Add Health) waves  and 
measures assessed  at each wave. 
 
Table 1. Wave I sociodemographic and baseline characteristics of individuals with and without 
history of adolescent chronic pain. Data source: Longitudinal study of adolescent to adult health. 
 
Table 2. Multivariate logistic regression analyses testing the association between adolescent 
chronic pain history and prescription opioid misuse in adulthood at Wave III and Wave IV.  
 
Table 3. Multivariate logistic regression analyses testing associations between hypothesized 
risk factors and prescription opioid misuse among participants with a history of chronic pain 
during adolescence. 
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Table 1.  
 
Characteristic Full sample No adolescent 
chronic pain 
Adolescent 
chronic pain 
p 
Sample (n) 14784 11610 3174  
Estimated population (million) 21.9 17.1 4.8  
Mean age at Wave I (years)  16.0 16.0 16.0 0.94 
Mean age at Wave IV (years) 28.9 28.9 28.9 0.76 
Sex (female %) 49.3 47.1 57.4 <0.0001 
Race and ethnicity (%)    0.25 
   White, non-Hispanic 65.6 65.2 67.5  
   Black, non-Hispanic 15.5 15.5 15.5  
   Hispanic  12.0 12.4 10.6  
   Other 6.8 7.0 6.4  
Mean income ($) 45665 46182 43994 0.11 
Mean depressive symptoms 
(range 0-60) 
11.4 10.4 14.9 <0.0001 
Mean anxiety symptoms (range 
0-20) 
2.3 2.0 3.5 <0.0001 
General health rated as fair-
poor (%) 
7.0 5.6 12.1 <0.0001 
Substance use (range 0-6) 1.1 1.0 1.4 <0.0001 
Childhood trauma exposures 
(range 0-9) 
0.4 0.4 0.6 <0.0001 
Legitimate opioid use during 
Wave IV (%) 
5.2 4.7 6.9 <0.001 
Prescription opioid misuse, 
Wave III (early adulthood) (%) 
19.9 18.8 24.0 <0.0001 
Prescription opioid misuse, 
Wave IV (adulthood) (%) 
28.3 27.0 33.0 <0.0001 
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Table 2.  
Characteristic Early adulthood (Wave III) Adulthood (Wave IV) 
 AOR 95% CI p AOR 95% CI p 
Adolescent chronic pain         
No (ref)    (ref)    
Yes 1.24 1.05 -1.46 0.013 1.19 1.04 -1.36 0.013 
Age 0.90 0.86 -0.95 <0.0001 0.88 0.85 -0.92 <0.0001 
Sex         
Male (ref)    (ref)    
Female 0.81 0.70 -0.94 0.006 0.76 0.66 -0.86 <0.0001 
Race and ethnicity         
White, non-Hispanic (ref)    (ref)    
Black, non-Hispanic 0.52 0.38 -0.72 <0.0001 0.39 0.29 -0.51 <0.0001 
Hispanic 0.53 0.41 -0.69 <0.0001 0.50 0.40 -0.62 <0.0001 
Other 0.87 0.65 -1.17 0.349 0.88 0.69 -1.13 0.311 
Income 1.00 1.00 -1.00 0.092 1.00 1.00 -1.00 0.416 
Depression 1.00 0.99 -1.01 0.911 1.00 0.99 -1.01 0.588 
Anxiety 0.99 0.95 -1.03 0.704 0.99 0.95 -1.03 0.487 
Health reported as fair-
poor 
        
No (ref)    (ref)    
Yes 0.96 0.71 -1.32 0.815 1.18 0.90 -1.56 0.223 
Substance use 1.21 1.16 -1.27 <0.0001 1.27 1.22 -1.33 <0.0001 
Childhood trauma 
exposures 
1.32 1.23 -1.42 <0.0001 1.31 1.21 -1.41 <0.0001 
Legitimate opioid use 
during Wave IV 
- - - - 1.95    1.53 -2.48 <0.0001 
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Table 3.  
Characteristic AOR 95% CI p 
Age 0.93 0.87 -1.00 0.065 
Sex     
Male (ref)    
Female 0.67 0.52 -0.86 0.002 
Race and ethnicity     
White, non-Hispanic (ref)    
Black, non-Hispanic 0.40 0.23 -0.69 0.001 
Hispanic 0.42 0.25 -0.71 0.001 
Other 1.40 0.86 -2.29 0.17 
Income 1.00 1.00 -1.00 0.284 
Depression 0.99 0.98 -1.01 0.473 
Anxiety 1.02 0.96 -1.08 0.563 
Health reported as fair-poor     
No (ref)    
Yes 1.01 0.65 -1.57 0.967 
Substance use 1.27 1.17 -1.39 <0.0001 
Childhood trauma exposures 1.38 1.21 -1.58 <0.0001 
 
 
 
 
 
 
